The primary objective from this ongoing open-label, single-center, neoadjuvant Window of Opportunity study is to evaluate tolerability, along with biomarker and tumor volume response to Verastem’s focal adhesion kinase inhibitor VS-6063 following either 12 days or 35 days of treatment in surgically-eligible patients with malignant pleural mesothelioma . “Results from this early-stage study show that single-agent VS-6063 was generally well tolerated as a neoadjuvant therapy in chemotherapy-naA ve patients,” said Dr. Bueno.
